Suchergebnisse - "Koruth, Roy"

PubPharm (7)

1

Estimating the Allocation of the Economic Value Generated by Utilization of All-Oral Direct-Acting Antivirals for Hepatitis C in the United States, 2015-2019

enthalten in: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | 2024

von Garrison, L. | Jiao, B. | Elsisi, Z. | +4

2

Comparative efficacy and safety of dabrafenib in combination with trametinib versus competing adjuvant therapies for high-risk melanoma

enthalten in: Journal of comparative effectiveness research | 2019

von Sharma, R. | Koruth, R. | Kanters, S. | +2

3

Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective

enthalten in: Journal of medical economics | 2019

von Gerbasi, M. | Stellato, D. | Ghate, S. | +6

CommentIn: J Med Econ. 2019 Dec;22(12):1241-1242. - PMID 31560259

4

Budget Impact of Dabrafenib and Trametinib in Combination as Adjuvant Treatment of BRAF V600E/K Mutation-Positive Melanoma from a U.S. Commercial Payer Perspective

enthalten in: Journal of managed care & specialty pharmacy | 2019

von Stellato, D. | Gerbasi, M. | Ndife, B. | +6

5

Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma : a multicountry retrospective chart review

enthalten in: Melanoma management | 2019

von Mohr, P. | Kiecker, F. | Soriano, V. | +18

6

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD) : a randomised, placebo-controlled, phase 3 trial

enthalten in: The Lancet. Oncology | 2019

von Schadendorf, D. | Hauschild, A. | Santinami, M. | +20

CommentIn: Lancet Oncol. 2019 May;20(5):611-612. - PMID 30928621

7

Method for Quantitative Refolding of the Link Module from Human TSG-6

enthalten in: Protein expression and purification | 1997

von Kahmann, J. | Koruth, R. | Day, A.

1
[1]